Divi's Laboratories Faces ₹570 Crore Tax Draft Order; Plans Appeal

Divi's Laboratories faces a potential income tax liability of up to ₹570.51 crores for FY2022-23. The pharmaceutical major received a Draft Assessment Order from the Income Tax Authority on March 20, 2026, with the company receiving communication on March 21, 2026.

Reader Takeaway: Tax demand of ₹570 Cr looms; company to appeal to contest.

What just happened (today’s filing)

Divi's Laboratories Limited disclosed receipt of a Draft Assessment Order from the Income Tax Authority for the Financial Year 2022-23 (Assessment Year 2023-24).

The order proposes additions/disallowances amounting to ₹570.51 crores concerning the company's returned income.

These proposed adjustments are primarily related to Transfer Pricing adjustments on specified domestic transactions and corporate tax adjustments.

The company is currently evaluating the order and intends to file an appeal with the appropriate authority within the stipulated time frame.

Why this matters

This development could lead to a significant additional income tax liability for Divi's Laboratories, impacting its profitability and cash flow if the appeal is unsuccessful.

The proposed additions signal scrutiny from tax authorities regarding the company's transfer pricing policies and corporate tax compliance.

Furthermore, the Draft Order indicates that penalty proceedings under Section 270A of the Income Tax Act will be initiated separately for alleged under-reporting of income.

The backstory (grounded)

Divi's Laboratories, a global leader in API manufacturing, has previously faced regulatory attention. In February 2019, the Income Tax Department conducted raids at its premises, though the company stated at the time that no irregularities were found.

More recently, in November 2023, the company received a GST demand notice of approximately ₹164 crore (later specified as ₹82 crore IGST demand plus interest and penalty) concerning an IGST refund. Divi's Laboratories had decided to appeal this notice.

Amidst these challenges, the company continues to invest in growth, with ongoing capacity and backward integration investments, having capitalized ₹776 crores in the 9-month period ending December 2025.

What changes now

• Shareholders will monitor the company's appeal process closely.
• The financial implications depend on the outcome of the appeal and any subsequent proceedings.
• The company's ability to navigate tax disputes will be tested.

Risks to watch

• The primary risk is the potential confirmation of the ₹570.51 crore tax demand, leading to a substantial liability.
• The initiation of penalty proceedings for alleged under-reporting of income poses an additional financial and reputational risk.
• The lengthy and uncertain nature of the appeal process itself can create sustained uncertainty for investors.

Peer comparison

Divi's Laboratories operates in a competitive landscape alongside peers like Laurus Labs, Granules India, and Aarti Drugs Ltd.

Laurus Labs, a major API manufacturer, has shown volatile earnings, with significant past declines but strong recent growth.

Granules India reported moderate revenue growth in Q4FY25, with net profit increasing by 17%.

Aarti Drugs Ltd recorded a 6.06% year-on-year revenue jump in Q3 FY26, with net profits up 9.42%.

While peers navigate their own growth and profitability paths, Divi's faces a specific tax-related overhang.

Context metrics (time-bound)

• Ongoing capacity and backward integration investments show continued commitment to expansion, with ₹776 crores capitalized in the 9-month period ending December 2025.

What to track next

• The company's formal appeal filing and the subsequent response from the tax authorities.
• Any further communications or interim orders related to the assessment or penalty proceedings.
• Management's commentary on the tax matter during future earnings calls.
• The final outcome of the appeal and its impact on the company's financial statements.